Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2009

01-08-2009 | Letter

AIT test has no problem in the detection of anti-ribosomal P – authors' response

Authors: Michael Mahler, Marvin J Fritzler

Published in: Arthritis Research & Therapy | Issue 4/2009

Login to get access

Excerpt

In a recent article, Jearn and Kim assessed the ability of indirect immunofluorescence on a novel human macrophage cell line (IT-1) in an autoimmune target (AIT) assay to predict the presence of anti-ribosomal P (anti-Rib-P) antibodies [1], based on a previously described cytoplasmic and/or nucleolar staining pattern [2]. Despite the clearance of the AIT test by the South Korea Food and Drug Administration, to the best of our knowledge this test is not widely used as a screening method – neither is it approved by the Food and Drug Administration (FDA) USA or is it a Communauté Européenne (CE) certified method for the detection of antinuclear antibodies. By contrast, many laboratories rely on HEp-2 cell substrates that are widely available as FDA and CE approved diagnostic kits from a variety of manufacturers. …
Literature
2.
go back to reference Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ: Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther. 2008, 10: R131-10.1186/ar2548.PubMedCentralCrossRefPubMed Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ: Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther. 2008, 10: R131-10.1186/ar2548.PubMedCentralCrossRefPubMed
3.
go back to reference Bonfa E, Gaburo N, Tavares AV, Cossermelli W: Comparison of five methods for the detection of antiribosomal P protein antibody. Braz J Med Biol Res. 1994, 27: 637-643.PubMed Bonfa E, Gaburo N, Tavares AV, Cossermelli W: Comparison of five methods for the detection of antiribosomal P protein antibody. Braz J Med Biol Res. 1994, 27: 637-643.PubMed
4.
go back to reference Desplat-Jego S, Bardin N, Larida B, Sanmarco M: Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods. Ann N Y Acad Sci. 2007, 1109: 245-255. 10.1196/annals.1398.030.CrossRefPubMed Desplat-Jego S, Bardin N, Larida B, Sanmarco M: Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods. Ann N Y Acad Sci. 2007, 1109: 245-255. 10.1196/annals.1398.030.CrossRefPubMed
5.
go back to reference Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E: Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab. 2005, 51: 517-521.PubMed Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E: Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab. 2005, 51: 517-521.PubMed
Metadata
Title
AIT test has no problem in the detection of anti-ribosomal P – authors' response
Authors
Michael Mahler
Marvin J Fritzler
Publication date
01-08-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2776

Other articles of this Issue 4/2009

Arthritis Research & Therapy 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine